Spinal Elements, a spine technology company, has announced the release of its Clutch interspinous process device. This new product further enhances the breadth of Spinal Elements’ thoracolumbar portfolio and offers surgeons more options for treatment of various posterior thoracolumbar pathologies, a press release states.
Clutch has been in use since shortly after its FDA 510(k) clearance in 2017, and is the only interspinous process device to maintain active compression against the spinous processes to resist loosening and migration. This is made possible through the device’s proprietary spring-activated mechanism, a “unique and clinically relevant feature” according to the company. Additionally, the device’s bone opposing surfaces are enhanced with clinically proven Titanium Bond technology, designed to provide immediate stability and long-term fixation.
“I have found interspinous process devices to be a very useful surgical option in my practice. Clutch has an ideal anatomic design that lets me confidently place the device in a more anterior position, fixating securely into the best quality bone,” says neurosurgeon Burak Ozgur (Newport Beach, California, USA).
Jason Blain, president and CEO of Spinal Elements adds, “Creating procedural solutions for improved patient outcomes is a critical requirement for every system we design and market. Clutch meets this need with what we believe to be a best-in-class design. I am excited for how this addition complements and expands our product portfolio.”
